Michael Eskew - Eli Lilly Independent Director
| LLY Stock | USD 749.92 3.49 0.46% |
Director
Mr. Michael L. Eskew is an Independent Director of the Company since 2008.
| Age | 71 |
| Tenure | 16 years |
| Address | Lilly Corporate Center, Indianapolis, IN, United States, 46285 |
| Phone | 317 276 2000 |
| Web | https://www.lilly.com |
Eli Lilly Management Efficiency
The company has Return on Asset of 0.1395 % which means that on every $100 spent on assets, it made $0.1395 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.6532 %, implying that it generated $0.6532 on every 100 dollars invested. Eli Lilly's management efficiency ratios could be used to measure how well Eli Lilly manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Eli Lilly's Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.12 in 2024, whereas Return On Capital Employed is likely to drop 0.25 in 2024. At this time, Eli Lilly's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 40.2 B in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 2.9 B in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Charles Prince | Johnson Johnson | 71 | |
| Steven Reid | Gold Fields Ltd | 64 | |
| BCompt BCom | Gold Fields Ltd | 57 | |
| Jennifer Doudna | Johnson Johnson | 57 | |
| Terence Goodlace | Gold Fields Ltd | 60 | |
| Peter Bacchus | Gold Fields Ltd | 51 | |
| Yunus Suleman | Gold Fields Ltd | 62 | |
| Steve Reid | Gold Fields Ltd | 63 | |
| Anne Mulcahy | Johnson Johnson | 68 | |
| Darius Adamczyk | Johnson Johnson | 55 | |
| Hubert Joly | Johnson Johnson | 61 | |
| Mary Beckerle | Johnson Johnson | 66 | |
| Ronald Williams | Johnson Johnson | 71 | |
| Alhassan Andani | Gold Fields Ltd | 58 | |
| Mark Weinberger | Johnson Johnson | 59 | |
| Philisiwe Sibiya | Gold Fields Ltd | 43 | |
| Carmen Letton | Gold Fields Ltd | 54 | |
| Ian Davis | Johnson Johnson | 70 | |
| Paul Schmidt | Gold Fields Ltd | 52 | |
| Marillyn Hewson | Johnson Johnson | 67 | |
| Mark McClellan | Johnson Johnson | 57 | |
Management Performance
| Return On Equity | 0.65 | ||||
| Return On Asset | 0.14 |
Eli Lilly Leadership Team
Elected by the shareholders, the Eli Lilly's board of directors comprises two types of representatives: Eli Lilly inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eli. The board's role is to monitor Eli Lilly's management team and ensure that shareholders' interests are well served. Eli Lilly's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eli Lilly's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kathi Seifert, Independent Director | ||
| Eric Dozier, Executive Diversity | ||
| Jamere Jackson, Independent Director | ||
| Joshua Smiley, Chief Financial Officer, Senior Vice President | ||
| Anat Hakim, Senior Vice President, General Counsel, Secretary | ||
| Johna Norton, Senior Vice President - Global Quality | ||
| Juan Luciano, Lead Independent Director | ||
| J Fyrwald, Independent Director | ||
| Alonzo Weems, Senior Vice President - Enterprise Risk Management, Chief Ethics and Compliance Officer | ||
| Jim Greffet, Head Strategy | ||
| Alfonso Zulueta, Senior Vice President and President - Emerging Markets business | ||
| Gabrielle Sulzberger, Independent Director | ||
| Anat Ashkenazi, Chief Financial Officer, Senior Vice President | ||
| Jeffrey Simmons, Senior Vice President and President - Elanco Animal Health | ||
| Anne White, Senior Vice President and Presidentident - Lilly Oncology | ||
| Mark MD, Senior Development | ||
| Leigh Pusey, Senior Vice President - Corporate Affairs and Communications | ||
| Melissa Barnes, Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer | ||
| Patrik Jonsson, Senior Vice President, Chief Customer Officer, President - Lilly Immunology, Lilly USA | ||
| Lucas Montarce, Executive CFO | ||
| Darin Moody, Dry Ingredient | ||
| William Kaelin, Independent Director | ||
| Karen Walker, Independent Director | ||
| Jacob Naarden, Senior Vice President, Chief Executive Officer - Loxo Oncology at Lilly, President - Lilly Oncology | ||
| Ilya Yuffa, Senior Vice President and President of Lilly Bio-Medicines | ||
| Bronwen Mantlo, Deputy VP | ||
| Raul Alvarez, Independent Director | ||
| Marschall Runge, Independent Director | ||
| Kimberly Johnson, Independent Director | ||
| Gordon Brooks, Controller VP | ||
| Anat JD, General VP | ||
| Myles ONeill, Senior Vice President and President - Manufacturing Operations | ||
| David Ricks, Senior Vice President and Presidentident - Lilly Bio-Medicines | ||
| Daniel Skovronsky, Senior Vice President, Chief Scientific and Medical Officer, President - Lilly Research Laboratories | ||
| Edgardo Hernandez, Senior Vice President and Presidentident - Manufacturing Operations | ||
| Diogo Rau, Senior Vice President Chief Information and Digital Officer | ||
| Donald Zakrowski, Senior Officer | ||
| Carolyn Bertozzi, Independent Director | ||
| Aarti Shah, Senior Vice President - Chief Information and Digital Officer | ||
| Jackson Tai, Independent Director | ||
| Michael Eskew, Independent Director | ||
| Martin MIBS, VP Projects | ||
| Katherine Baicker, Independent Director | ||
| Stephen Fry, Senior Vice President - Human Resources and Diversity | ||
| Michael Mason, Senior Vice President and President Lilly Diabetes | ||
| David MD, Chief Officer | ||
| Winselow Tucker, Senior Loxo |
Eli Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Eli Lilly a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.65 | ||||
| Return On Asset | 0.14 | ||||
| Profit Margin | 0.20 % | ||||
| Operating Margin | 0.40 % | ||||
| Current Valuation | 720.35 B | ||||
| Shares Outstanding | 949.32 M | ||||
| Shares Owned By Insiders | 0.15 % | ||||
| Shares Owned By Institutions | 83.29 % | ||||
| Number Of Shares Shorted | 6.62 M | ||||
| Price To Earning | 54.92 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Eli Stock Analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.